LT
Lorenzo Trippa
stat.MEResearch Designstat.APBayes TheoremClinical Trials as TopicGlioblastomaMultiple MyelomaglioblastomaSmoldering Multiple MyelomaBrain Neoplasms
On Valency
published · living versionsW_gdqusmwz·v1 · currentpublished
Preprints & journals
151 papers in the corpus · 2011–2026Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial.42728379 · Nadeem, Omar, Cordas Dos Santos, David M, Magidson, Sophie et al.2026 · 0 citationsNature medicine. 2026;32(10):3812-3822
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.42693161 · Perron, Noé, Foster, Kane, Mouhieddine, Tarek H et al.2026 · 0 citationsLeukemia. 2026;40(11):2622-2626
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.42172567 · Rudra Gupta, Tulika, Polley, Mei-Yin C, Redd, Robert et al.2026 · 0 citationsJournal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026;44(21):2048-2058
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial.42098120 · Hanna, Glenn J, Gupta, Tulika R, Trippa, Lorenzo et al.2026 · 3 citationsNature communications. 2026;17(1)
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.42010117 · Nadeem, Omar, Cordas Dos Santos, David M, Nikiforow, Sarah et al.2026 · 11 citationsNature medicine. 2026;32(7):2420-2429
Myeloma Precursors Erode Durable Immunity: Results of the IMPACT study.42040964 · Perron, Noé, Aranha, Michelle P, Wu, Ting et al.2026 · 0 citationsResearch square. 2026
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.41951609 · Nadeem, Omar, Aranha, Michelle P, Redd, Robert A et al.2026 · 0 citationsNature communications. 2026;17(1)
Q-approximation of operating characteristics of clinical trial designs2603.20022v2 · Susanna Gentile, Daniel E. Schwartz, Riddhiman Saha et al.2026 · 0 citationsarXiv
Incorporating data from multiple ongoing trials for Bayesian two-stage phase II single-arm studies.40838464 · Halabi, Susan, Choi, Taehwa, Garrett-Mayer, Elizabeth et al.2025 · 2 citationsClinical trials (London, England). 2025;22(6):667-675
Identifying appropriate external control datasets in support of future glioblastoma clinical trials leveraging external data.39921868 · Rahman, Rifaquat, Ventz, Steffen, Redd, Robert et al.2025 · 4 citationsNeuro-oncology. 2025;27(6):1507-1518
Harmonized Estimation of Subgroup-Specific Treatment Effects in Randomized Trials: The Use of External Control Data.41929638 · Schwartz, Daniel, Saha, Riddhiman, Ventz, Steffen et al.2026 · 2 citationsJournal of the Royal Statistical Society. Series B, Statistical methodology. 2026;88(1):143-170
Leveraging External Data for Testing Experimental Therapies with Biomarker Interactions in Randomized Clinical Trials.42099548 · Ren, B, Ferrari, F, Fortini, S et al.2026 · 0 citationsBiometrika. 2026;113(1)
Comparing Fourteen Behavioral Science Electronic Health Record Deprescribing Tools in Older Adults: NUDGE-EHR Adaptive Trial.40614073 · Lauffenburger, Julie C, Isaac, Thomas, Trippa, Lorenzo et al.2025 · 7 citationsJournal of the American Geriatrics Society. 2025;73(10):3031-3043
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).40502745 · Chabrun, Floris, Schwartz, Daniel, Gentile, Susanna et al.2026 · 7 citationsResearch square. 2025
Bayesian multi-study non-negative matrix factorization for mutational signatures.40241112 · Grabski, Isabella N, Trippa, Lorenzo, Parmigiani, Giovanni2025 · 4 citationsGenome biology. 2025;26(1):98
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.39879593 · Guglielmetti, Lorenzo, Khan, Uzma, Velásquez, Gustavo E et al.2025 · 94 citationsThe New England journal of medicine. 2025;392(5):468-482
A cautious use of auxiliary outcomes for decision-making in randomized clinical trials2501.04187v3 · Massimiliano Russo, Steffen Ventz, Lorenzo Trippa2025 · 0 citationsarXiv
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.39753553 · Nadeem, Omar, Aranha, Michelle P, Redd, Robert et al.2025 · 20 citationsNature communications. 2025;16(1):358
Informative censoring in externally controlled clinical trials: a potential source of bias.39754980 · Rudra Gupta, T, Schwartz, D E, Saha, R et al.2025 · 2 citationsESMO open. 2025;10(1):104094
Serum free light chains in a racially diverse population including African Americans and populations from South Africa.39571144 · Bertamini, Luca, Alberge, Jean-Baptiste, Lee, David J et al.2025 · 11 citationsBlood. 2025;145(8):840-849
Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology.39432880 · Russo, Massimiliano, Mariani, Francesco, Cleary, James M et al.2024 · 0 citationsJCO precision oncology. 2024;8:e2400275
Leveraging external data in the analysis of randomized controlled trials: a comparative analysis2408.13409v2 · Gopal Kotecha, Daniel E. Schwartz, Steffen Ventz et al.2024 · 0 citationsarXiv
Unleashing the power of clinical trial data: a proposal for enhancing informed consent and data sharing.38856720 · Trippa, Lorenzo, Khozin, Sean2024 · 0 citationsThe oncologist. 2024;29(8):651-652
Uncertainty directed factorial clinical trials.38330084 · Kotecha, Gopal, Ventz, Steffen, Fortini, Sandra et al.2024 · 1 citationBiostatistics (Oxford, England). 2024;25(3):833-851
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors.38904277 · Plotkin, Scott R, Yohay, Kaleb H, Nghiemphu, Phioanh L et al.2024 · 68 citationsThe New England journal of medicine. 2024;390(24):2284-2294
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.38699307 · Nadeem, Omar, Aranha, Michelle P, Redd, Robert et al.2024 · 6 citationsmedRxiv : the preprint server for health sciences. 2024
Nine-month, all-oral regimens for rifampin-resistant tuberculosis10.1101/2024.01.29.24301679v1 · Guglielmetti, L., Khan, U., Velasquez, G. E. et al.2024 · 13 citationsmedRxiv
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.38092228 · Spring, L M, Tolaney, S M, Fell, G et al.2024 · 86 citationsAnnals of oncology : official journal of the European Society for Medical Oncology. 2024;35(3):293-301
Clinical trials that leverage external data: Do we need more transparent protocols and statistical plans?38008030 · Schwartz, Daniel Evan, Essaouabi, Hanna, Trippa, Lorenzo2023 · 1 citationEuropean journal of cancer (Oxford, England : 1990). 2024;196:113443
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.37722087 · Rahman, Rifaquat, Trippa, Lorenzo, Lee, Eudocia Q et al.2023 · 59 citationsJournal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41(36):5524-5535
Bayesian combinatorial MultiStudy factor analysis.37786772 · Grabski, Isabella N, Vito, Roberta De, Trippa, Lorenzo et al.2024 · 9 citationsThe annals of applied statistics. 2023;17(3):2212-2235
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma.37200026 · Rahman, Rifaquat, Ventz, Steffen, Trippa, Lorenzo2023 · 3 citationsJAMA oncology. 2023;9(7):1006-1007
Looking ahead in early-phase trial design to improve the drug development process: examples in oncology.37386450 · Vanderbeek, Alyssa M, Redd, Robert A, Ventz, Steffen et al.2023 · 3 citationsBMC medical research methodology. 2023;23(1):151
Sensitivity Analyses of Clinical Trial Designs: Selecting Scenarios and Summarizing Operating Characteristics.38680760 · Han, Larry, Arfè, Andrea, Trippa, Lorenzo2025 · 7 citationsThe American statistician. 2024;78(1):76-87
Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials.36939557 · Rahman, Rifaquat, Ventz, Steffen, Redd, Robert et al.2023 · 9 citationsClinical cancer research : an official journal of the American Association for Cancer Research. 2023;29(12):2194-2198
Comment: Advancing Clinical Trials with Novel Designs and Implementations.37654478 · Trippa, Lorenzo, Xu, Yanxun2026 · 1 citationStatistical science : a review journal of the Institute of Mathematical Statistics. 2023;38(2):216-218
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.36858677 · Cowan, Annie, Ferrari, Federico, Freeman, Samuel S et al.2023 · 86 citationsThe Lancet. Haematology. 2023;10(3):e203-e212
Combining Breast Cancer Risk Prediction Models.36831433 · Guan, Zoe, Huang, Theodore, McCarthy, Anne Marie et al.2025 · 18 citationsCancers. 2023;15(4)
Cross-Study Replicability in Cluster Analysis.37885824 · Masoero, Lorenzo, Thomas, Emma, Parmigiani, Giovanni et al.2023 · 5 citationsStatistical science : a review journal of the Institute of Mathematical Statistics. 2023;38(2):303-316
Validation of Predictive Analyses for Interim Decisions in Clinical Trials.36848613 · Avalos-Pacheco, Alejandra, Ventz, Steffen, Arfè, Andrea et al.2023 · 4 citationsJCO precision oncology. 2023;7:e2200606
Prospectively shared control data across concurrent randomised clinical trials.36621117 · Kotecha, Gopal, Ventz, Steffen, Trippa, Lorenzo2023 · 3 citationsEuropean journal of cancer (Oxford, England : 1990). 2023;181:18-20
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.36379208 · Sklavenitis-Pistofidis, Romanos, Aranha, Michelle P, Redd, Robert A et al.2022 · 70 citationsCancer cell. 2022;40(11):1358-1373.e8
The design and evaluation of hybrid controlled trials that leverage external data and randomization.36184621 · Ventz, Steffen, Khozin, Sean, Louv, Bill et al.2022 · 35 citationsNature communications. 2022;13(1):5783
A validation of models for prediction of pathogenic variants in mismatch repair genes.35997715 · Shyr, Cathy, Blackford, Amanda L, Huang, Theodore et al.2022 · 6 citationsGenetics in medicine : official journal of the American College of Medical Genetics. 2022;24(10):2155-2166
Novel Clinical Trial Designs in Neuro-Oncology.35969361 · Saraf, Anurag, Trippa, Lorenzo, Rahman, Rifaquat2022 · 9 citationsNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2022;19(6):1844-1854
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.35705541 · Bustoros, Mark, Anand, Shankara, Sklavenitis-Pistofidis, Romanos et al.2022 · 35 citationsNature communications. 2022;13(1):3449
Empirical Evaluations of Clinical Trial Designs.35544143 · Trippa, Lorenzo, Bacallado, Sergio2022 · 1 citationJAMA network open. 2022;5(5):e2211620
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia.34847227 · Tahri, Sabrin, Mouhieddine, Tarek H, Redd, Robert et al.2022 · 27 citationsBlood advances. 2022;6(7):2230-2235
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.35344689 · El-Khoury, Habib, Lee, David J, Alberge, Jean-Baptiste et al.2022 · 94 citationsThe Lancet. Haematology. 2022;9(5):e340-e349
Approximating the Operating Characteristics of Bayesian Uncertainty Directed Trial Designs.37711732 · Bonsaglio, Marta, Fortini, Sandra, Ventz, Steffen et al.2023 · 0 citationsJournal of statistical planning and inference. 2022;221:90-99
Career total: 354 works. 151 are in this corpus.Showing the 50 most recent.
Profile built from the corpus for this byline.
Author records are still filling in while the Hub is in alpha. If this is your page, you'll be able to claim it soon. Spot a mistake? Tell us.